You are viewing an inactive listing

Rochester, Minnesota 55905

  • Obesity

Purpose:

Will oral supplementation with Omega 3 free fatty acids in obese Barrett's esophagus subjects downregulate pro-neoplastic and pro-inflammatory pathways in the esophagus to anti-inflammatory pathway?


Criteria:

Inclusion Criteria - Presence of BE defined as ≥ 1 cm of visible columnar mucosa in the distal esophagus with intestinal metaplasia on histology. - Absence of high grade dysplasia or EAC on baseline histology. - BMI > 30 kg/m2 or waist circumference > 102 cm in men, > 88 cm in women. - Ability to give informed consent. Exclusion Criteria - Allergy to ω3 FFAs, fish or shellfish. - Presence of high grade dysplasia or cancer on histology. - Pregnant and or breastfeeding women - Presence of esophagitis on initial endoscopy or symptoms of refractory GERD (heartburn or regurgitation ≥ 2 times a week) indicative of uncontrolled gastroesophageal reflux. - Inability to give informed consent. - Currently taking Omega3 FFA as prescription. - Anti-coagulant therapy (Plavix, Warfarin, Coumadin) - AST or ALT level > three times upper limit of normal at baseline - LDL > 200 mg/dl at baseline. - INR > 2


NCT ID:

NCT01733147


Primary Contact:

Principal Investigator
Prasad Iyer, MD
Mayo Clinic


Backup Contact:

N/A


Location Contact:

Rochester, Minnesota 55905
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.